2006
Methylation of the insulin‐like growth factor binding protein‐3 gene and prognosis of epithelial ovarian cancer
WILEY A, KATSAROS D, FRACCHIOLI S, YU H. Methylation of the insulin‐like growth factor binding protein‐3 gene and prognosis of epithelial ovarian cancer. International Journal Of Gynecological Cancer 2006, 16: 210-218. PMID: 16445635, DOI: 10.1111/j.1525-1438.2006.00299.x.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorBiopsy, NeedleCarcinomaCohort StudiesDNA MethylationFemaleHumansImmunohistochemistryInsulin-Like Growth Factor Binding Protein 3Multivariate AnalysisNeoplasm StagingOvarian NeoplasmsOvariectomyProbabilityPrognosisProportional Hazards ModelsRetrospective StudiesRisk FactorsSensitivity and SpecificitySurvival RateConceptsIGFBP-3 promoter methylationInsulin-like growth factorIGFBP-3Disease progressionOvarian cancerGrowth factorPromoter methylationEarly-stage ovarian cancerEpithelial ovarian cancer patientsResidual tumor sizeEarly-stage diseaseIGFBP-3 expressionEpithelial ovarian cancerOvarian cancer patientsUseful prognostic markerOvarian cancer progressionIGFBP-3 promoterMethylation-specific polymerase chain reactionIGFBP-3 genePathologic variablesTumor sizeDisease stageCancer patientsPolymerase chain reactionPrognostic marker
2000
Relapse and cure rates of prostate cancer patients after radical prostatectomy and 5 years of follow-up
Vassilikos E, Yu H, Trachtenberg J, Nam R, Narod S, Bromberg I, Diamandis E. Relapse and cure rates of prostate cancer patients after radical prostatectomy and 5 years of follow-up. Clinical Biochemistry 2000, 33: 115-123. PMID: 10751589, DOI: 10.1016/s0009-9120(99)00099-5.Peer-Reviewed Original ResearchMeSH KeywordsAgedDisease-Free SurvivalFluorescent Antibody TechniqueFollow-Up StudiesHumansMaleMiddle AgedNeoplasm InvasivenessNeoplasm StagingProportional Hazards ModelsProstate-Specific AntigenProstatectomyProstatic NeoplasmsRecurrenceRegression AnalysisReproducibility of ResultsSensitivity and SpecificityTime FactorsTreatment OutcomeConceptsProstate cancer patientsRadical prostatectomySerum PSACancer patientsPSA assaysUltrasensitive prostate specific antigenPre-operative PSAGroup of patientsSerial serum samplesEarly therapeutic interventionSeminal vesicle invasionSurgical margin positivityProstate-specific antigenRegular PSAUltrasensitive PSAPSA increaseMargin positivityClinical stageGleason scorePrognostic indicatorCapsular invasionTissue involvementTumor volumePatientsFast relapse
1999
Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination
Yu H, Levesque M, Clark G, Diamandis E. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination. British Journal Of Cancer 1999, 81: 490-495. PMID: 10507775, PMCID: PMC2362935, DOI: 10.1038/sj.bjc.6690720.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsBiomarkers, TumorBreast NeoplasmsCarcinomaChemotherapy, AdjuvantCombined Modality TherapyDisease-Free SurvivalDNA ReplicationEnzyme-Linked Immunosorbent AssayFemaleFollow-Up StudiesGene Expression Regulation, NeoplasticGenes, p53HumansLife TablesLymphatic MetastasisMastectomyMultivariate AnalysisNeoplasm ProteinsNeoplasm Recurrence, LocalNeoplasms, Hormone-DependentPloidiesPrognosisProportional Hazards ModelsProstate-Specific AntigenRadiotherapy, AdjuvantReceptors, EstrogenReceptors, ProgesteroneRiskSensitivity and SpecificitySurvival AnalysisSurvival RateTreatment OutcomeTumor Suppressor Protein p53ConceptsEnzyme-linked immunosorbent assayDisease-free survivalBreast cancer patientsCancer patientsRelative riskCox proportional hazards regression analysisProstate-specific antigen expressionProportional hazards regression analysisReceipt of chemotherapyProgesterone receptor statusSteroid hormone receptor analysisHazards regression analysisRecent clinical evidenceLog-rank testKaplan-Meier plotsOverall survival probabilityHormone receptor analysisPrimary breast carcinomaQuantitative enzyme-linked immunosorbent assayProstate-specific antigenP53 expression statusAssessment of p53Breast cancer prognosisS-phase fractionExpression of p53
1998
Immunofluorometrically determined p53 accumulation as a prognostic indicator in italian breast cancer patients
Levesque M, Katsaros D, Yu H, Giai M, Genta F, Roagna R, Ponzone R, Massobrio M, Sismondi P, Diamandis E. Immunofluorometrically determined p53 accumulation as a prognostic indicator in italian breast cancer patients. International Journal Of Cancer 1998, 79: 147-152. PMID: 9583729, DOI: 10.1002/(sici)1097-0215(19980417)79:2<147::aid-ijc9>3.0.co;2-t.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAnalysis of VarianceAntibody SpecificityBreast NeoplasmsCarcinoma, Ductal, BreastCombined Modality TherapyDisease-Free SurvivalFemaleFluorescent Antibody TechniqueHumansLymphatic MetastasisMiddle AgedMultivariate AnalysisNeoplasm StagingPredictive Value of TestsPrognosisReceptors, EstrogenReceptors, ProgesteroneRecurrenceSensitivity and SpecificityTime FactorsTumor Suppressor Protein p53ConceptsP53 proteinItalian breast cancer patientsProgesterone receptor expression statusMultivariate Cox regression analysisP53-negative patientsP53-positive patientsReceptor expression statusDisease-free survivalLymph node statusSteroid hormone receptor analysisCox regression analysisBreast cancer patientsEstrogen receptor expressionHormone receptor analysisCM-1 antibodySensitive immunofluorometric assayBreast cancer prognosisP53 protein accumulationOverall survivalPatient ageIndependent predictorsHistologic typeNode statusPrognostic valueShort patients
1996
Ultrasensitive prostate-specific antigen assays and their clinical application.
Diamandis E, Yu H, Melegos D. Ultrasensitive prostate-specific antigen assays and their clinical application. Clinical Chemistry 1996, 42: 853-857. PMID: 8665675, DOI: 10.1093/clinchem/42.6.853.Peer-Reviewed Original ResearchUltrasensitive detection of prostate-specific antigen by a time-resolved immunofluorometric assay and the Immulite immunochemiluminescent third-generation assay: potential applications in prostate and breast cancers.
Ferguson R, Yu H, Kalyvas M, Zammit S, Diamandis E. Ultrasensitive detection of prostate-specific antigen by a time-resolved immunofluorometric assay and the Immulite immunochemiluminescent third-generation assay: potential applications in prostate and breast cancers. Clinical Chemistry 1996, 42: 675-684. PMID: 8653891, DOI: 10.1093/clinchem/42.5.675.Peer-Reviewed Original ResearchConceptsTime-resolved immunofluorometric assayProstate-specific antigenL PSAPotential applicationsUltrasensitive time-resolved immunofluorometric assayUltrasensitive detectionPSA immunoreactivityImmunofluorometric assayWide dynamic rangeFree prostate-specific antigenPostradical prostatectomy patientsEstrogen receptor positivityUltrasensitive PSA assaysDynamic rangePSA changeReceptor positivityProstatectomy patientsProstate cancerBreast cancerPSA assaysHook effectLow analytical limitsSignificant associationMonoclonal antibodiesSerum samplesAssay of prostate-specific antigen from whole blood spotted on filter paper and application to prostate cancer screening.
Hoffman B, Yu H, Diamandis E. Assay of prostate-specific antigen from whole blood spotted on filter paper and application to prostate cancer screening. Clinical Chemistry 1996, 42: 536-544. PMID: 8605670, DOI: 10.1093/clinchem/42.4.536.Peer-Reviewed Original ResearchConceptsProstate-specific antigenProstate cancerOccult prostate cancerWhole bloodWhole blood concentrationsExtracts of bloodFilter paper procedureMicrograms/L.Cancer screeningPSA recoverySy/xBloodPlasma fractionConcentration of PSARegression analysisCancerAntigenCentralized laboratoriesMicroL of bufferMicroLFilter paperPaper discsHematocritRecoveryMonths
1995
Quantification of creatine kinase BB isoenzyme in tumor cytosols and serum with an ultrasensitive time-resolved immunofluorometric technique
Zarghami N, Yu H, Diamandis E, Sutherland D. Quantification of creatine kinase BB isoenzyme in tumor cytosols and serum with an ultrasensitive time-resolved immunofluorometric technique. Clinical Biochemistry 1995, 28: 243-253. PMID: 7554242, DOI: 10.1016/0009-9120(95)00010-7.Peer-Reviewed Original ResearchConceptsCK-BB levelsBreast tumor cytosolsCreatine kinase BBCK-BBProstate cancerTumor cytosolsCancer patientsEstrogen sensitivityHealthy subjectsSerum CK-BB levelsActive prostate cancerSensitive immunofluorometric procedurePost-radical prostatectomyProstate cancer patientsSerum CK-BBCK-BB isoenzymeSteroid hormone receptorsSerum PSAProgesterone receptorRadical prostatectomyBreast cancerMale volunteersHealthy volunteersPatientsBreast tumorsOriginal Articles: Prostate Cancer: Measurement of Serum Prostate Specific Antigen Levels in Women and in Prostatectomized Men With an Ultrasensitive Immunoassay Technique
Yu H, Diamandis E. Original Articles: Prostate Cancer: Measurement of Serum Prostate Specific Antigen Levels in Women and in Prostatectomized Men With an Ultrasensitive Immunoassay Technique. Journal Of Urology 1995, 153: 1004-1008. PMID: 7531781, DOI: 10.1016/s0022-5347(01)67622-5.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAge DistributionAgedAged, 80 and overFemaleFluoroimmunoassayHumansMaleMiddle AgedProstate-Specific AntigenProstatectomySensitivity and SpecificitySex DistributionConceptsSerum prostate-specific antigenProstate-specific antigenPSA levelsDetectable serum prostate specific antigenDistribution of PSAHigher serum prostate-specific antigenSerum prostate-specific antigen levelHealthy female blood donorsMeasurable prostate-specific antigenPostoperative prostate-specific antigenPreoperative prostate-specific antigenProstate-specific antigen levelYear of surgeryEvidence of relapseFemale blood donorsSpecific antigen levelsAge 50 yearsProstate cancer patientsHospitalized womenPatients 50Recurrent tumorsAntigen levelsHistological gradeCancer patientsRadical prostatectomy
1993
Ultrasensitive time-resolved immunofluorometric assay of prostate-specific antigen in serum and preliminary clinical studies.
Yu H, Diamandis E. Ultrasensitive time-resolved immunofluorometric assay of prostate-specific antigen in serum and preliminary clinical studies. Clinical Chemistry 1993, 39: 2108-2114. PMID: 7691442, DOI: 10.1093/clinchem/39.10.2108.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAlkaline PhosphataseAntibodies, MonoclonalChromatography, High Pressure LiquidEdetic AcidFemaleFluoroimmunoassayHumansMaleMiddle AgedNeoplasm Recurrence, LocalProstate-Specific AntigenProstatectomyProstatic NeoplasmsQuality ControlReference ValuesSensitivity and SpecificityTerbiumConceptsL PSAPolyclonal detection antibodyUltrasensitive time-resolved immunofluorometric assaySensitive prostate specific antigenPSA antibodyDetection antibodyTime-resolved fluorometryTime-resolved immunofluorometric assayUltrasensitive methodProstate-specific antigenMicrotiter wellsImmunofluorometric assayClinical applicationStreptavidinExtreme sensitivityAssays